Fluticasona propionato
Fluticasone Propionate
Fluticasone propionate (trifluorinated glucocorticoid)
También conocido como: Flovent · Advair Diskus · Cutovate · Flixotide · Flixonase · Flutivate · CCI-18781 · fluticasoni propionas
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Adjunctive treatment of chronic tracheobronchial disease (excessive side effects from oral steroids) | 110 microgram or 220 microgram (1 puff) | Inhalation | q12h | — | 🌎 NA |
| Adjunctive treatment of chronic tracheobronchial disease | 2 puffs of the 220 micrograms/puff MDI | Inhalation | q12h | — | 🌎 NA |
- Adjunctive treatment of chronic tracheobronchial disease (excessive side effects from oral steroids): Use a delivery device (e.g., AeroDawg). Ensure a tightly fitting face mask and count 7-10 respirations after actuating the MDI into the spacer.
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Treatment of feline 'asthma' | one puff of the 44 micrograms/puff MDI | Inhalation | q12h | — | 🌎 NA |
| Feline asthma (signs occurring more than once per week) | one puff of 110 micrograms fluticasone MDI | Inhalation | q12h | — | 🌎 NA |
- Treatment of feline 'asthma': Initially try this dose. Study showed 44, 110, and 220 mcg all significantly reduced eosinophils in airway lavage fluid.
- Feline asthma (signs occurring more than once per week): Use a delivery device (e.g., AeroKat) with a spacer. Cats with more serious disease may require the 220 micrograms MDI. Breathe in and out 7-10 times with mask in place. Give prednisolone at 1-2 mg/kg PO twice daily for 5-7 days initially, then taper over 2-3 months.
Caballos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Inflammatory airway disease (IAD) in young racehorses | Weeks 1 and 2: 2200 micrograms (10 puffs) twice daily. Weeks 3 and 4: 2200 micrograms (10 puffs) once daily. | Inhalation | q12h then q24h | 4 weeks | 🌎 NA |
| Moderate recurrent airway obstruction (RAO/heaves) | Week 3: 2200 micrograms (10 puffs) twice daily. Week 4: 2200 micrograms (10 puffs) once daily. End of 4 weeks (if good response): 2200 micrograms (10 puffs) once every other day. | Inhalation | q12h, then q24h, then EOD | Maintenance | 🌎 NA |
| Prevention of exacerbations of RAO | 6 mg | Inhalation | q12h | — | 🌎 NA |
- Inflammatory airway disease (IAD) in young racehorses: Use a delivery device (e.g., Aeromask or Equine-haler). Recheck in 4 weeks to determine further treatment.
- Moderate recurrent airway obstruction (RAO/heaves): Begin stringent environmental control and systemic prednisone. Add fluticasone at week 3 with salmeterol 210 mcg (10 puffs).
- Prevention of exacerbations of RAO: Using the EquineHaler. Highly likely that a lower dose can be used.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
El propionato de fluticasona es un glucocorticoide sintético potente utilizado principalmente en medicina veterinaria como aerosol inhalado.
- Usos principales: Es altamente eficaz para el manejo de enfermedades inflamatorias crónicas de las vías respiratorias, como el asma felina, la enfermedad traqueobronquial crónica en perros y la obstrucción recurrente de las vías respiratorias (RAO/heaves) o la enfermedad inflamatoria de las vías respiratorias (IAD) en caballos. Las formulaciones nasales también pueden utilizarse para la rinosinusitis crónica relacionada con alergias.
- Ventaja clínica: Debido a que se administra directamente a la mucosa respiratoria a través de un inhalador de dosis medida (MDI) y una cámara espaciadora específica para la especie, proporciona excelentes efectos antiinflamatorios locales mientras minimiza significativamente los efectos secundarios sistémicos típicamente asociados con los esteroides orales o inyectables.
- Potencia: Posee una afinidad por los receptores de glucocorticoides humanos que es 18 veces mayor que la de la dexametasona.
Mecanismo de acción
Fluticasone exerts its effects by binding to cytosolic glucocorticoid receptors in the respiratory mucosa.
Mechanism Pathway: Receptor binding → Translocation of the receptor-ligand complex to the nucleus → Alteration of gene transcription → Inhibition of pro-inflammatory mediators (such as cytokines, prostaglandins, and leukotrienes) → Decreased airway inflammation, reduced mucosal edema, and lowered airway hyperreactivity.
Note: The drug is highly lipophilic, allowing for prolonged retention in lung tissue, and undergoes extensive first-pass metabolism, which limits systemic bioavailability if swallowed.
Seguridad y advertencias
Contraindicaciones
- Hypersensitivity to fluticasone
- Acute bronchospasm or status asthmaticus (not a rescue inhaler)
Efectos adversos
- Pharyngitis (reported in humans)
- Upper respiratory infections (reported in humans)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression (rare with inhaled therapy, but possible with chronic high doses)
- Cushingoid effects (with chronic overdosage)
- Paradoxical bronchospasm (rare)
Precauciones
When transferring patients from systemic steroid therapy to inhaled steroids, wean slowly off systemic therapy to avoid acute adrenal insufficiency. Prepare to cover patients with additional systemic steroid therapy during periods of acute stress, severe asthma attacks occurring during the withdrawal stage, or after transfer to inhaled steroids. Fluticasone is not useful for acute bronchospasm. Use with caution in nursing dams. FDA Category C for pregnancy; use only when benefits clearly outweigh risks.
Interacciones farmacológicas
Inhibits CYP3A4 isoenzymes; theoretically could increase systemic fluticasone levels.
May decrease the metabolism of fluticasone, potentially increasing systemic exposure.
Monitorización
- Clinical efficacy (reduction in coughing, wheezing, or respiratory effort)
- Signs of HPA axis suppression or cushingoid changes (rare with inhaled therapy)
Farmacocinética
Absorción
In humans, when administered via the lung, about 30% is absorbed into the systemic circulation. Peak plasma concentrations of 0.1 to 1 ng/mL seen after 880 mcg dose.
Distribución
Volume of distribution averages 4.2 L/kg. It is 91% bound to human plasma proteins.
Metabolismo
Metabolized via hepatic cytochrome P450 3A4 isoenzymes to a metabolite with negligible pharmacologic activity.
Eliminación
Terminal elimination half-life is about 8 hours (in humans). Most of the drug is excreted in the feces as parent drug and metabolites.
Sobredosis
Acute overdoses of this medication are unlikely to require treatment. Chronic overdoses could result in significant HPA axis suppression and cushingoid effects.
Productos disponibles
Formulaciones
- Metered dose inhaler (MDI) aerosol
- Dry powder for inhalation
- Nasal spray/solution
- Topical cream and ointment
Etiquetado para humanos
- Fluticasone Propionate aerosol for inhalation: 44 mcg, 110 mcg, and 220 mcg per actuation (Flovent HFA)
- Fluticasone Propionate/Salmeterol Powder for Inhalation: 100/50 mcg, 250/50 mcg, 500/50 mcg (Advair Diskus)
- Fluticasone Propionate/Salmeterol Aerosol for Inhalation: 45/21 mcg, 115/21 mcg, 230/21 mcg
- Nasal solutions, topical creams, and ointments
Estado regulador
Sin datos reguladores para: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store between 2-30°C (36-86°F); protect from freezing and direct sunlight. Store canister with the mouthpiece down.
Información para el cliente
Importante: Este medicamento es un controlador preventivo para la inflamación de las vías respiratorias. No es un inhalador de rescate para ataques agudos de asma.
- Preparación: Agite bien el cartucho antes de usarlo. Si es posible, deje que el cartucho alcance la temperatura ambiente antes de la administración.
- Administración: Debe utilizarse con un dispositivo espaciador adecuado para la especie de su mascota (p. ej., AeroKat®, AeroDawg®). Coloque la mascarilla suavemente sobre la boca y la nariz del animal, presione el inhalador para llenar el espaciador y permita que el animal respire con la mascarilla puesta durante 7 a 10 respiraciones normales antes de retirarla.
- Almacenamiento: No perfore ni incinere el cartucho.
- Duración: Una prescripción estándar de una inhalación dos veces al día durará aproximadamente 2 meses.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.